Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 Report Highlights:
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 Report Highlights:
- Market Potential Of VISTA Inhibitors
- Market Commercialization Assessment Scenario
- Partnerships, Collaborations & Agreements
- Global VISTA Inhibitors Clinical Pipeline By Biomarker, Indication, Company, Country & Phase
- Global VISTA Inhibitors Market Dynamics
- Insight On 15 Companies Involved In Development Of VISTA Inhibiting Drugs
- Role Of VISTA As Inhibitory & Costimulatory Checkpoint
Download Report: https://www.kuickresearch.com/report-vista-inhibitors-vista-immune-checkpoint-vista-antibody-clinical-trial-vista-protein
In the last two decades, a number of immune checkpoint proteins have been discovered that have drastically changed the way cancer is treated. PD-1 and CTLA-4 formed the first generation of immune checkpoint proteins and have been used as targets for many modern immunotherapies, including antibodies, antibody-drug conjugates and cell therapies. The commercial and clinical success of these targeted therapies have encouraged the research to identify further checkpoint proteins, and fruitful results have been obtained in the recent years as new protein targets such as LAG-3, TIGIT and TIM-3 have been brought to attention in the science and consequently, cancer therapeutics domain. VISTA is another protein that has been gaining attention for its distinctive properties that make it different from other checkpoint proteins.
VISTA (V-domain Ig suppressor of T cell activation) protein was found to have both inhibitory and stimulatory effects on the immune system. The protein is expressed highly on myeloid cells that infiltrate cancer tumors and its presence has also been observed on tumor cells, though mostly in undetectable concentrations. High VISTA expression is associated with poor prognosis and detrimental malignancy characteristics. In animal studies of mouse models, VISTA inhibition was seen to be more effective than both CTLA-4 and PD-1 inhibition, which is why the protein is now being actively explored for its therapeutic potential.
Gauging its possibility to be used as an oncology target from data obtained in preclinical studies, many pharmaceutical companies now have drug candidates in their pipelines which have been designed to specifically target the VISTA protein. Some of these include Hummingbird Bioscience, Aurigene, Sensei Biotherapeutics and Pierre Fabre. All candidates in the global pipeline are in their early phases of clinical trials and are being evaluated for the treatment of solid cancers. According to the global clinical trials database, most of these are monoclonal antibodies that work by preventing the interactions between the protein and its ligands, both in physiological and acidic environments, for the protein is said to interact with different biomolecules at different pH. These interactions are required for it to exert its inhibitory effects in the body.
Researchers have successfully guessed the inhibitory role VISTA plays on the immune system; the mechanisms of action, however, remain unknown and so are its binding partners. As mentioned above, the protein interacts with different molecules at different pH and there are many locations in the body where acidic pH can be found, therefore it is highly likely that the protein interacts with a different set of proteins that are possibly still unknown to us. Though some confirmed and unconfirmed binding partners have been pinpointed to interact with VISTA, more research is needed to confirm these results and to fully understand the working mechanism of the protein. This will help in helping researches and drug developers to copiously appreciate the therapeutic potential of VISTA.
More or less, it is now known that the VISTA signaling is non-redundant with PD-1/PD-L1 axis and CTLA-4 signaling which is why combination therapy with inhibitors of these proteins has been suggested for the treatment of cancer to generate optimal immune responses against cancer tumors. In this time, when immune checkpoint inhibition is one of the most widely accepted cancer treatment approaches, VISTA-targeting opens another door of opportunities for us. Combination therapies have shown ample evidence to be a reliable treatment approach and blockade of more than two checkpoint proteins has demonstrated excellent results in the past. As more VISTA inhibitors enter into clinical trials and progress to later stages, it is anticipated that the clinical landscape will expand rapidly as more trials will be conducted to assess the combinations of different checkpoint inhibitors.
At this time of scientific and technological developments, many favorable market factors are driving the development of VISTA inhibitors globally. The widespread acceptance and use of immune checkpoint inhibitors remains one of the top factors. Moreover, the investments in the research and development activities have increased drastically in the last few years because of the unmet need of treatment approaches cancer has presented to us. These factors are expected to continue in the future as well, joined by newer factors, which will take the market beyond our current expectations.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com